Latest Neuroprotection Stories
Scientists have discovered a compound that restores the capacity to form new memories in aging rats, likely by improving the survival of newborn neurons in the brain's memory hub.
RICHMOND, Calif., July 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has been awarded a second round of funding by The Michael J.
FREMONT, Calif., June 28 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof.
FREMONT, Calif., June 24 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK: "QPI-1007, an ocular neuroprotective siRNA for ameliorating RGC (retinal ganglion cell) loss," presented by Elena Feinstein, Chief Scientific...
JACKSONVILLE, Fla., May 24 /PRNewswire/ -- Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program.
Researchers explore potential benefits of caffeine in special supplement to the Journal of Alzheimer's Disease.
LONDON, May 11, 2010 /PRNewswire/ -- The subject of extensive studies across the world, Resveratrol is proving to be a major talking point in the scientific community.
NEW YORK, April 23 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced more than $3 million in previously unannounced awards ending the first quarter of 2010.
A unique cell type that supports and surrounds (ensheathes) neurons within the nose (olfactory system) known as olfactory ensheathing cells (OECs), possess the ability to regenerate, are relatively easy to obtain, and have become prime candidates for transplantation to repair a number of lesions in the central nervous system (CNS).
Richard Borgens and his colleagues from the Center for Paralysis Research at the Purdue School of Veterinary Medicine have a strong record of inventing therapies for treating nerve damage.
- totally perplexed and mixed up.